NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acume

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their s

Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, wh

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their s

EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared t

NEWTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company dev

NEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen

JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicate

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty bio

ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option u

ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under

Acumen Pharmaceuticals is a clinical-stage Alzheimer's biotech built around sabirnetug. I believe 20

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Tr

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript

Acumen Pharmaceuticals NASDAQ: ABOS said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on trac

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.33) per share which beat the a

NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen

NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clini

NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen

The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technical

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compar

Shares of Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) have been assigned a consens

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript

ACUMEN PHARMACEUTICALS, INC.Up to 10,833,331 shares of Common Stock    This prospectus relates to th

BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and mainta

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.41) per share which beat the a

NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) --  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acu

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing no

NBIS: 17% | Nebius Announced 5-Year $12B AI Infrastructure Agreement With Meta To Provide Dedicated

Proceeds from the financing are expected to primarily support Acumen's Enhanced Brain Delivery (

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a

BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and raises

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a

B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy

Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The

B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.68) per share which missed the